Key Points
- Ardent Health CFO Alfred Lumsdaine bought 10,000 shares at $8.81 each, totaling $88,100, boosting his direct ownership to 329,183 shares, a 3.13% increase.
- The purchase came as ARDT shares were up 1.5% and trading around $8.81, near the low end of their 12-month range of $7.71 to $15.48.
- Ardent Health recently reported better-than-expected quarterly results, with EPS of $0.28 versus $0.18 expected and revenue of $1.60 billion, while analysts currently have a consensus rating of Hold and an average price target of $14.21.
Ardent Health, Inc. (NYSE:ARDT - Get Free Report) CFO Alfred Lumsdaine bought 10,000 shares of the business's stock in a transaction dated Friday, June 5th. The shares were bought at an average cost of $8.81 per share, with a total value of $88,100.00. Following the purchase, the chief financial officer directly owned 329,183 shares of the company's stock, valued at approximately $2,900,102.23. This represents a 3.13% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Ardent Health Stock Up 1.5%
ARDT opened at $8.81 on Tuesday. The company has a market cap of $1.26 billion, a PE ratio of 9.28, a price-to-earnings-growth ratio of 1.94 and a beta of 0.85. Ardent Health, Inc. has a twelve month low of $7.71 and a twelve month high of $15.48. The company has a 50-day moving average price of $9.40 and a 200 day moving average price of $9.11. The company has a quick ratio of 2.00, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.
Ardent Health (NYSE:ARDT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.10. Ardent Health had a return on equity of 13.85% and a net margin of 2.09%.The company had revenue of $1.60 billion for the quarter, compared to analysts' expectations of $1.58 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Sell-side analysts expect that Ardent Health, Inc. will post 1.12 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ardent Health
A number of institutional investors have recently added to or reduced their stakes in the stock. Goldentree Asset Management LP boosted its stake in Ardent Health by 99.7% during the fourth quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company's stock worth $20,302,000 after buying an additional 1,150,000 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Ardent Health by 8.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,769,335 shares of the company's stock worth $23,444,000 after acquiring an additional 134,513 shares during the period. Vanguard Group Inc. boosted its position in shares of Ardent Health by 44.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,352,676 shares of the company's stock valued at $17,923,000 after acquiring an additional 416,348 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Ardent Health by 6.6% in the third quarter. Millennium Management LLC now owns 1,269,605 shares of the company's stock valued at $16,822,000 after purchasing an additional 78,861 shares during the period. Finally, Bridgeway Capital Management LLC increased its position in Ardent Health by 108.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 946,571 shares of the company's stock worth $8,358,000 after purchasing an additional 491,961 shares during the last quarter.
Wall Street Analyst Weigh In
Several analysts recently commented on the company. Zacks Research upgraded Ardent Health from a "strong sell" rating to a "hold" rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded Ardent Health from a "hold" rating to a "buy" rating in a report on Saturday, May 16th. Royal Bank Of Canada dropped their target price on shares of Ardent Health from $14.00 to $13.00 and set an "outperform" rating for the company in a report on Monday, March 9th. UBS Group increased their target price on shares of Ardent Health from $13.00 to $13.50 and gave the company a "buy" rating in a research report on Thursday, May 7th. Finally, Leerink Partners decreased their price target on shares of Ardent Health from $16.00 to $15.00 and set an "outperform" rating on the stock in a research note on Friday, March 6th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $14.21.
View Our Latest Research Report on ARDT
Ardent Health Company Profile
(
Get Free Report)
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company's integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
